Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603811 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults
A Phase 1 study, sponsored by VaxInnate Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00603811 is a Phase 1 study that has completed, run by VaxInnate Corporation. The registered enrollment target is 60 participants.
The verdict
NCT00603811, a Phase 1 study, has completed, sponsored by VaxInnate Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety and immunogenicity of VAX102 \[Flagellin.HuM2e\], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VAX102 [Flagellin.HuM2e]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603811
The ClinicalTrials.gov registry entry for NCT00603811 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00603811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603811 about?
NCT00603811 is a clinical study titled "Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults". This study will evaluate the safety and immunogenicity of VAX102 \[Flagellin.HuM2e\], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
What is the current status of trial NCT00603811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00603811?
The interventions under investigation include: Placebo (BIOLOGICAL), VAX102 [Flagellin.HuM2e] (BIOLOGICAL).
Who is sponsoring clinical trial NCT00603811?
This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.